# The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age

> **NCT03114982** · PHASE2 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 152 (actual)

## Conditions studied

- Varicella

## Interventions

- **BIOLOGICAL:** NBP608
- **BIOLOGICAL:** Varivax

## Key facts

- **NCT ID:** NCT03114982
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2016-07
- **Final completion:** 2016-11
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2017-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03114982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03114982, "The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03114982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*